COVID-19 Impact on Global Non-oncology Biopharmaceuticals Market Size, Status and Forecast 2020-2026
- BMR3871655
- 129 Pages
- June 2020
- Healthcare
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Non-oncology Biopharmaceuticals market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Non-oncology Biopharmaceuticals industry.
Based on our recent survey, we have several different scenarios about the Non-oncology Biopharmaceuticals YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ 279770 million in 2019. The market size of Non-oncology Biopharmaceuticals will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Non-oncology Biopharmaceuticals market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Non-oncology Biopharmaceuticals market in terms of revenue.
Players, stakeholders, and other participants in the global Non-oncology Biopharmaceuticals market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global Non-oncology Biopharmaceuticals market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global Non-oncology Biopharmaceuticals market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Non-oncology Biopharmaceuticals market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Non-oncology Biopharmaceuticals market.
The following players are covered in this report:
Roche
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Novartis
Merck
Teva
Eli Lilly
Bristol-Myers Squibb
GlaxoSmithKline
UCB Pharma
Amgen
AbbVie
Takeda
AstraZeneca
Mylan
LEO Pharma
Boehringer Ingelheim
Alexion Pharmaceuticals
Elusys Therapeutics
Swedish Orphan Biovitrum
Biogen
Non-oncology Biopharmaceuticals Breakdown Data by Type
Biologics
Biosimilars
Non-oncology Biopharmaceuticals Breakdown Data by Application
Immunology
Endocrinology
Others
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Non-oncology Biopharmaceuticals Revenue
1.4 Market Analysis by Type
1.4.1 Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Biologics
1.4.3 Biosimilars
1.5 Market by Application
1.5.1 Global Non-oncology Biopharmaceuticals Market Share by Application: 2020 VS 2026
1.5.2 Immunology
1.5.3 Endocrinology
1.5.4 Others
1.6 Coronavirus Disease 2019 (Covid-19): Non-oncology Biopharmaceuticals Industry Impact
1.6.1 How the Covid-19 is Affecting the Non-oncology Biopharmaceuticals Industry
1.6.1.1 Non-oncology Biopharmaceuticals Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Non-oncology Biopharmaceuticals Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Non-oncology Biopharmaceuticals Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends by Regions
2.1 Non-oncology Biopharmaceuticals Market Perspective (2015-2026)
2.2 Non-oncology Biopharmaceuticals Growth Trends by Regions
2.2.1 Non-oncology Biopharmaceuticals Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Non-oncology Biopharmaceuticals Historic Market Share by Regions (2015-2020)
2.2.3 Non-oncology Biopharmaceuticals Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Non-oncology Biopharmaceuticals Market Growth Strategy
2.3.6 Primary Interviews with Key Non-oncology Biopharmaceuticals Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Non-oncology Biopharmaceuticals Players by Market Size
3.1.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue (2015-2020)
3.1.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by Players (2015-2020)
3.1.3 Global Non-oncology Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Non-oncology Biopharmaceuticals Market Concentration Ratio
3.2.1 Global Non-oncology Biopharmaceuticals Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Non-oncology Biopharmaceuticals Revenue in 2019
3.3 Non-oncology Biopharmaceuticals Key Players Head office and Area Served
3.4 Key Players Non-oncology Biopharmaceuticals Product Solution and Service
3.5 Date of Enter into Non-oncology Biopharmaceuticals Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
4.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Type (2015-2020)
4.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2021-2026)
5 Non-oncology Biopharmaceuticals Breakdown Data by Application (2015-2026)
5.1 Global Non-oncology Biopharmaceuticals Market Size by Application (2015-2020)
5.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Non-oncology Biopharmaceuticals Market Size (2015-2020)
6.2 Non-oncology Biopharmaceuticals Key Players in North America (2019-2020)
6.3 North America Non-oncology Biopharmaceuticals Market Size by Type (2015-2020)
6.4 North America Non-oncology Biopharmaceuticals Market Size by Application (2015-2020)
7 Europe
7.1 Europe Non-oncology Biopharmaceuticals Market Size (2015-2020)
7.2 Non-oncology Biopharmaceuticals Key Players in Europe (2019-2020)
7.3 Europe Non-oncology Biopharmaceuticals Market Size by Type (2015-2020)
7.4 Europe Non-oncology Biopharmaceuticals Market Size by Application (2015-2020)
8 China
8.1 China Non-oncology Biopharmaceuticals Market Size (2015-2020)
8.2 Non-oncology Biopharmaceuticals Key Players in China (2019-2020)
8.3 China Non-oncology Biopharmaceuticals Market Size by Type (2015-2020)
8.4 China Non-oncology Biopharmaceuticals Market Size by Application (2015-2020)
9 Japan
9.1 Japan Non-oncology Biopharmaceuticals Market Size (2015-2020)
9.2 Non-oncology Biopharmaceuticals Key Players in Japan (2019-2020)
9.3 Japan Non-oncology Biopharmaceuticals Market Size by Type (2015-2020)
9.4 Japan Non-oncology Biopharmaceuticals Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Non-oncology Biopharmaceuticals Market Size (2015-2020)
10.2 Non-oncology Biopharmaceuticals Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Non-oncology Biopharmaceuticals Market Size by Type (2015-2020)
10.4 Southeast Asia Non-oncology Biopharmaceuticals Market Size by Application (2015-2020)
11 India
11.1 India Non-oncology Biopharmaceuticals Market Size (2015-2020)
11.2 Non-oncology Biopharmaceuticals Key Players in India (2019-2020)
11.3 India Non-oncology Biopharmaceuticals Market Size by Type (2015-2020)
11.4 India Non-oncology Biopharmaceuticals Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Non-oncology Biopharmaceuticals Market Size (2015-2020)
12.2 Non-oncology Biopharmaceuticals Key Players in Central & South America (2019-2020)
12.3 Central & South America Non-oncology Biopharmaceuticals Market Size by Type (2015-2020)
12.4 Central & South America Non-oncology Biopharmaceuticals Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Roche
13.1.1 Roche Company Details
13.1.2 Roche Business Overview and Its Total Revenue
13.1.3 Roche Non-oncology Biopharmaceuticals Introduction
13.1.4 Roche Revenue in Non-oncology Biopharmaceuticals Business (2015-2020))
13.1.5 Roche Recent Development
13.2 Sanofi
13.2.1 Sanofi Company Details
13.2.2 Sanofi Business Overview and Its Total Revenue
13.2.3 Sanofi Non-oncology Biopharmaceuticals Introduction
13.2.4 Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
13.2.5 Sanofi Recent Development
13.3 Johnson & Johnson
13.3.1 Johnson & Johnson Company Details
13.3.2 Johnson & Johnson Business Overview and Its Total Revenue
13.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Introduction
13.3.4 Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
13.3.5 Johnson & Johnson Recent Development
13.4 Pfizer
13.4.1 Pfizer Company Details
13.4.2 Pfizer Business Overview and Its Total Revenue
13.4.3 Pfizer Non-oncology Biopharmaceuticals Introduction
13.4.4 Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
13.4.5 Pfizer Recent Development
13.5 Novo Nordisk
13.5.1 Novo Nordisk Company Details
13.5.2 Novo Nordisk Business Overview and Its Total Revenue
13.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Introduction
13.5.4 Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
13.5.5 Novo Nordisk Recent Development
13.6 Novartis
13.6.1 Novartis Company Details
13.6.2 Novartis Business Overview and Its Total Revenue
13.6.3 Novartis Non-oncology Biopharmaceuticals Introduction
13.6.4 Novartis Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
13.6.5 Novartis Recent Development
13.7 Merck
13.7.1 Merck Company Details
13.7.2 Merck Business Overview and Its Total Revenue
13.7.3 Merck Non-oncology Biopharmaceuticals Introduction
13.7.4 Merck Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
13.7.5 Merck Recent Development
13.8 Teva
13.8.1 Teva Company Details
13.8.2 Teva Business Overview and Its Total Revenue
13.8.3 Teva Non-oncology Biopharmaceuticals Introduction
13.8.4 Teva Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
13.8.5 Teva Recent Development
13.9 Eli Lilly
13.9.1 Eli Lilly Company Details
13.9.2 Eli Lilly Business Overview and Its Total Revenue
13.9.3 Eli Lilly Non-oncology Biopharmaceuticals Introduction
13.9.4 Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
13.9.5 Eli Lilly Recent Development
13.10 Bristol-Myers Squibb
13.10.1 Bristol-Myers Squibb Company Details
13.10.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
13.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Introduction
13.10.4 Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
13.10.5 Bristol-Myers Squibb Recent Development
13.11 GlaxoSmithKline
10.11.1 GlaxoSmithKline Company Details
10.11.2 GlaxoSmithKline Business Overview and Its Total Revenue
10.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Introduction
10.11.4 GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
10.11.5 GlaxoSmithKline Recent Development
13.12 UCB Pharma
10.12.1 UCB Pharma Company Details
10.12.2 UCB Pharma Business Overview and Its Total Revenue
10.12.3 UCB Pharma Non-oncology Biopharmaceuticals Introduction
10.12.4 UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
10.12.5 UCB Pharma Recent Development
13.13 Amgen
10.13.1 Amgen Company Details
10.13.2 Amgen Business Overview and Its Total Revenue
10.13.3 Amgen Non-oncology Biopharmaceuticals Introduction
10.13.4 Amgen Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
10.13.5 Amgen Recent Development
13.14 AbbVie
10.14.1 AbbVie Company Details
10.14.2 AbbVie Business Overview and Its Total Revenue
10.14.3 AbbVie Non-oncology Biopharmaceuticals Introduction
10.14.4 AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
10.14.5 AbbVie Recent Development
13.15 Takeda
10.15.1 Takeda Company Details
10.15.2 Takeda Business Overview and Its Total Revenue
10.15.3 Takeda Non-oncology Biopharmaceuticals Introduction
10.15.4 Takeda Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
10.15.5 Takeda Recent Development
13.16 AstraZeneca
10.16.1 AstraZeneca Company Details
10.16.2 AstraZeneca Business Overview and Its Total Revenue
10.16.3 AstraZeneca Non-oncology Biopharmaceuticals Introduction
10.16.4 AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
10.16.5 AstraZeneca Recent Development
13.17 Mylan
10.17.1 Mylan Company Details
10.17.2 Mylan Business Overview and Its Total Revenue
10.17.3 Mylan Non-oncology Biopharmaceuticals Introduction
10.17.4 Mylan Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
10.17.5 Mylan Recent Development
13.18 LEO Pharma
10.18.1 LEO Pharma Company Details
10.18.2 LEO Pharma Business Overview and Its Total Revenue
10.18.3 LEO Pharma Non-oncology Biopharmaceuticals Introduction
10.18.4 LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
10.18.5 LEO Pharma Recent Development
13.19 Boehringer Ingelheim
10.19.1 Boehringer Ingelheim Company Details
10.19.2 Boehringer Ingelheim Business Overview and Its Total Revenue
10.19.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Introduction
10.19.4 Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
10.19.5 Boehringer Ingelheim Recent Development
13.20 Alexion Pharmaceuticals
10.20.1 Alexion Pharmaceuticals Company Details
10.20.2 Alexion Pharmaceuticals Business Overview and Its Total Revenue
10.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Introduction
10.20.4 Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
10.20.5 Alexion Pharmaceuticals Recent Development
13.21 Elusys Therapeutics
10.21.1 Elusys Therapeutics Company Details
10.21.2 Elusys Therapeutics Business Overview and Its Total Revenue
10.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Introduction
10.21.4 Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
10.21.5 Elusys Therapeutics Recent Development
13.22 Swedish Orphan Biovitrum
10.22.1 Swedish Orphan Biovitrum Company Details
10.22.2 Swedish Orphan Biovitrum Business Overview and Its Total Revenue
10.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Introduction
10.22.4 Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
10.22.5 Swedish Orphan Biovitrum Recent Development
13.23 Biogen
10.23.1 Biogen Company Details
10.23.2 Biogen Business Overview and Its Total Revenue
10.23.3 Biogen Non-oncology Biopharmaceuticals Introduction
10.23.4 Biogen Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
10.23.5 Biogen Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Non-oncology Biopharmaceuticals Key Market Segments
Table 2. Key Players Covered: Ranking by Non-oncology Biopharmaceuticals Revenue
Table 3. Ranking of Global Top Non-oncology Biopharmaceuticals Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Biologics
Table 6. Key Players of Biosimilars
Table 7. COVID-19 Impact Global Market: (Four Non-oncology Biopharmaceuticals Market Size Forecast Scenarios)
Table 8. Opportunities and Trends for Non-oncology Biopharmaceuticals Players in the COVID-19 Landscape
Table 9. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 10. Key Regions/Countries Measures against Covid-19 Impact
Table 11. Proposal for Non-oncology Biopharmaceuticals Players to Combat Covid-19 Impact
Table 12. Global Non-oncology Biopharmaceuticals Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 13. Global Non-oncology Biopharmaceuticals Market Size by Regions (US$ Million): 2020 VS 2026
Table 14. Global Non-oncology Biopharmaceuticals Market Size by Regions (2015-2020) (US$ Million)
Table 15. Global Non-oncology Biopharmaceuticals Market Share by Regions (2015-2020)
Table 16. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 17. Global Non-oncology Biopharmaceuticals Market Share by Regions (2021-2026)
Table 18. Market Top Trends
Table 19. Key Drivers: Impact Analysis
Table 20. Key Challenges
Table 21. Non-oncology Biopharmaceuticals Market Growth Strategy
Table 22. Main Points Interviewed from Key Non-oncology Biopharmaceuticals Players
Table 23. Global Non-oncology Biopharmaceuticals Revenue by Players (2015-2020) (Million US$)
Table 24. Global Non-oncology Biopharmaceuticals Market Share by Players (2015-2020)
Table 25. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-oncology Biopharmaceuticals as of 2019)
Table 26. Global Non-oncology Biopharmaceuticals by Players Market Concentration Ratio (CR5 and HHI)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Non-oncology Biopharmaceuticals Product Solution and Service
Table 29. Date of Enter into Non-oncology Biopharmaceuticals Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Non-oncology Biopharmaceuticals Market Size by Type (2015-2020) (Million US$)
Table 32. Global Non-oncology Biopharmaceuticals Market Size Share by Type (2015-2020)
Table 33. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2021-2026)
Table 34. Global Non-oncology Biopharmaceuticals Market Size Share by Application (2015-2020)
Table 35. Global Non-oncology Biopharmaceuticals Market Size by Application (2015-2020) (Million US$)
Table 36. Global Non-oncology Biopharmaceuticals Market Size Share by Application (2021-2026)
Table 37. North America Key Players Non-oncology Biopharmaceuticals Revenue (2019-2020) (Million US$)
Table 38. North America Key Players Non-oncology Biopharmaceuticals Market Share (2019-2020)
Table 39. North America Non-oncology Biopharmaceuticals Market Size by Type (2015-2020) (Million US$)
Table 40. North America Non-oncology Biopharmaceuticals Market Share by Type (2015-2020)
Table 41. North America Non-oncology Biopharmaceuticals Market Size by Application (2015-2020) (Million US$)
Table 42. North America Non-oncology Biopharmaceuticals Market Share by Application (2015-2020)
Table 43. Europe Key Players Non-oncology Biopharmaceuticals Revenue (2019-2020) (Million US$)
Table 44. Europe Key Players Non-oncology Biopharmaceuticals Market Share (2019-2020)
Table 45. Europe Non-oncology Biopharmaceuticals Market Size by Type (2015-2020) (Million US$)
Table 46. Europe Non-oncology Biopharmaceuticals Market Share by Type (2015-2020)
Table 47. Europe Non-oncology Biopharmaceuticals Market Size by Application (2015-2020) (Million US$)
Table 48. Europe Non-oncology Biopharmaceuticals Market Share by Application (2015-2020)
Table 49. China Key Players Non-oncology Biopharmaceuticals Revenue (2019-2020) (Million US$)
Table 50. China Key Players Non-oncology Biopharmaceuticals Market Share (2019-2020)
Table 51. China Non-oncology Biopharmaceuticals Market Size by Type (2015-2020) (Million US$)
Table 52. China Non-oncology Biopharmaceuticals Market Share by Type (2015-2020)
Table 53. China Non-oncology Biopharmaceuticals Market Size by Application (2015-2020) (Million US$)
Table 54. China Non-oncology Biopharmaceuticals Market Share by Application (2015-2020)
Table 55. Japan Key Players Non-oncology Biopharmaceuticals Revenue (2019-2020) (Million US$)
Table 56. Japan Key Players Non-oncology Biopharmaceuticals Market Share (2019-2020)
Table 57. Japan Non-oncology Biopharmaceuticals Market Size by Type (2015-2020) (Million US$)
Table 58. Japan Non-oncology Biopharmaceuticals Market Share by Type (2015-2020)
Table 59. Japan Non-oncology Biopharmaceuticals Market Size by Application (2015-2020) (Million US$)
Table 60. Japan Non-oncology Biopharmaceuticals Market Share by Application (2015-2020)
Table 61. Southeast Asia Key Players Non-oncology Biopharmaceuticals Revenue (2019-2020) (Million US$)
Table 62. Southeast Asia Key Players Non-oncology Biopharmaceuticals Market Share (2019-2020)
Table 63. Southeast Asia Non-oncology Biopharmaceuticals Market Size by Type (2015-2020) (Million US$)
Table 64. Southeast Asia Non-oncology Biopharmaceuticals Market Share by Type (2015-2020)
Table 65. Southeast Asia Non-oncology Biopharmaceuticals Market Size by Application (2015-2020) (Million US$)
Table 66. Southeast Asia Non-oncology Biopharmaceuticals Market Share by Application (2015-2020)
Table 67. India Key Players Non-oncology Biopharmaceuticals Revenue (2019-2020) (Million US$)
Table 68. India Key Players Non-oncology Biopharmaceuticals Market Share (2019-2020)
Table 69. India Non-oncology Biopharmaceuticals Market Size by Type (2015-2020) (Million US$)
Table 70. India Non-oncology Biopharmaceuticals Market Share by Type (2015-2020)
Table 71. India Non-oncology Biopharmaceuticals Market Size by Application (2015-2020) (Million US$)
Table 72. India Non-oncology Biopharmaceuticals Market Share by Application (2015-2020)
Table 73. Central & South America Key Players Non-oncology Biopharmaceuticals Revenue (2019-2020) (Million US$)
Table 74. Central & South America Key Players Non-oncology Biopharmaceuticals Market Share (2019-2020)
Table 75. Central & South America Non-oncology Biopharmaceuticals Market Size by Type (2015-2020) (Million US$)
Table 76. Central & South America Non-oncology Biopharmaceuticals Market Share by Type (2015-2020)
Table 77. Central & South America Non-oncology Biopharmaceuticals Market Size by Application (2015-2020) (Million US$)
Table 78. Central & South America Non-oncology Biopharmaceuticals Market Share by Application (2015-2020)
Table 79. Roche Company Details
Table 80. Roche Business Overview
Table 81. Roche Product
Table 82. Roche Revenue in Non-oncology Biopharmaceuticals Business (2015-2020) (Million US$)
Table 83. Roche Recent Development
Table 84. Sanofi Company Details
Table 85. Sanofi Business Overview
Table 86. Sanofi Product
Table 87. Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2015-2020) (Million US$)
Table 88. Sanofi Recent Development
Table 89. Johnson & Johnson Company Details
Table 90. Johnson & Johnson Business Overview
Table 91. Johnson & Johnson Product
Table 92. Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2015-2020) (Million US$)
Table 93. Johnson & Johnson Recent Development
Table 94. Pfizer Company Details
Table 95. Pfizer Business Overview
Table 96. Pfizer Product
Table 97. Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2015-2020) (Million US$)
Table 98. Pfizer Recent Development
Table 99. Novo Nordisk Company Details
Table 100. Novo Nordisk Business Overview
Table 101. Novo Nordisk Product
Table 102. Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2015-2020) (Million US$)
Table 103. Novo Nordisk Recent Development
Table 104. Novartis Company Details
Table 105. Novartis Business Overview
Table 106. Novartis Product
Table 107. Novartis Revenue in Non-oncology Biopharmaceuticals Business (2015-2020) (Million US$)
Table 108. Novartis Recent Development
Table 109. Merck Company Details
Table 110. Merck Business Overview
Table 111. Merck Product
Table 112. Merck Revenue in Non-oncology Biopharmaceuticals Business (2015-2020) (Million US$)
Table 113. Merck Recent Development
Table 114. Teva Business Overview
Table 115. Teva Product
Table 116. Teva Company Details
Table 117. Teva Revenue in Non-oncology Biopharmaceuticals Business (2015-2020) (Million US$)
Table 118. Teva Recent Development
Table 119. Eli Lilly Company Details
Table 120. Eli Lilly Business Overview
Table 121. Eli Lilly Product
Table 122. Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2015-2020) (Million US$)
Table 123. Eli Lilly Recent Development
Table 124. Bristol-Myers Squibb Company Details
Table 125. Bristol-Myers Squibb Business Overview
Table 126. Bristol-Myers Squibb Product
Table 127. Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2015-2020) (Million US$)
Table 128. Bristol-Myers Squibb Recent Development
Table 129. GlaxoSmithKline Company Details
Table 130. GlaxoSmithKline Business Overview
Table 131. GlaxoSmithKline Product
Table 132. GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2015-2020) (Million US$)
Table 133. GlaxoSmithKline Recent Development
Table 134. UCB Pharma Company Details
Table 135. UCB Pharma Business Overview
Table 136. UCB Pharma Product
Table 137. UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2015-2020) (Million US$)
Table 138. UCB Pharma Recent Development
Table 139. Amgen Company Details
Table 140. Amgen Business Overview
Table 141. Amgen Product
Table 142. Amgen Revenue in Non-oncology Biopharmaceuticals Business (2015-2020) (Million US$)
Table 143. Amgen Recent Development
Table 144. AbbVie Company Details
Table 145. AbbVie Business Overview
Table 146. AbbVie Product
Table 147. AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2015-2020) (Million US$)
Table 148. AbbVie Recent Development
Table 149. Takeda Company Details
Table 150. Takeda Business Overview
Table 151. Takeda Product
Table 152. Takeda Revenue in Non-oncology Biopharmaceuticals Business (2015-2020) (Million US$)
Table 153. Takeda Recent Development
Table 154. AstraZeneca Company Details
Table 155. AstraZeneca Business Overview
Table 156. AstraZeneca Product
Table 157. AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2015-2020) (Million US$)
Table 158. AstraZeneca Recent Development
Table 159. Mylan Company Details
Table 160. Mylan Business Overview
Table 161. Mylan Product
Table 162. Mylan Revenue in Non-oncology Biopharmaceuticals Business (2015-2020) (Million US$)
Table 163. Mylan Recent Development
Table 164. LEO Pharma Company Details
Table 165. LEO Pharma Business Overview
Table 166. LEO Pharma Product
Table 167. LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2015-2020) (Million US$)
Table 168. LEO Pharma Recent Development
Table 169. Boehringer Ingelheim Company Details
Table 170. Boehringer Ingelheim Business Overview
Table 171. Boehringer Ingelheim Product
Table 172. Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2015-2020) (Million US$)
Table 173. Boehringer Ingelheim Recent Development
Table 174. Alexion Pharmaceuticals Company Details
Table 175. Alexion Pharmaceuticals Business Overview
Table 176. Alexion Pharmaceuticals Product
Table 177. Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2015-2020) (Million US$)
Table 178. Alexion Pharmaceuticals Recent Development
Table 179. Elusys Therapeutics Company Details
Table 180. Elusys Therapeutics Business Overview
Table 181. Elusys Therapeutics Product
Table 182. Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2015-2020) (Million US$)
Table 183. Elusys Therapeutics Recent Development
Table 184. Swedish Orphan Biovitrum Company Details
Table 185. Swedish Orphan Biovitrum Business Overview
Table 186. Swedish Orphan Biovitrum Product
Table 187. Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2015-2020) (Million US$)
Table 188. Swedish Orphan Biovitrum Recent Development
Table 189. Biogen Company Details
Table 190. Biogen Business Overview
Table 191. Biogen Product
Table 192. Biogen Revenue in Non-oncology Biopharmaceuticals Business (2015-2020) (Million US$)
Table 193. Biogen Recent Development
Table 194. Research Programs/Design for This Report
Table 195. Key Data Information from Secondary Sources
Table 196. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-oncology Biopharmaceuticals Market Share by Type: 2020 VS 2026
Figure 2. Biologics Features
Figure 3. Biosimilars Features
Figure 4. Global Non-oncology Biopharmaceuticals Market Share by Application: 2020 VS 2026
Figure 5. Immunology Case Studies
Figure 6. Endocrinology Case Studies
Figure 7. Others Case Studies
Figure 8. Non-oncology Biopharmaceuticals Report Years Considered
Figure 9. Global Non-oncology Biopharmaceuticals Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Non-oncology Biopharmaceuticals Market Share by Regions: 2020 VS 2026
Figure 11. Global Non-oncology Biopharmaceuticals Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Non-oncology Biopharmaceuticals Market Share by Players in 2019
Figure 14. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-oncology Biopharmaceuticals as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Non-oncology Biopharmaceuticals Revenue in 2019
Figure 16. North America Non-oncology Biopharmaceuticals Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Non-oncology Biopharmaceuticals Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Non-oncology Biopharmaceuticals Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Non-oncology Biopharmaceuticals Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Non-oncology Biopharmaceuticals Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Non-oncology Biopharmaceuticals Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Non-oncology Biopharmaceuticals Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 24. Roche Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2015-2020)
Figure 25. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 26. Sanofi Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2015-2020)
Figure 27. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. Johnson & Johnson Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2015-2020)
Figure 29. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Pfizer Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2015-2020)
Figure 31. Novo Nordisk Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Novo Nordisk Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2015-2020)
Figure 33. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Novartis Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2015-2020)
Figure 35. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Merck Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2015-2020)
Figure 37. Teva Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Teva Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2015-2020)
Figure 39. Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Eli Lilly Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2015-2020)
Figure 41. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Bristol-Myers Squibb Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2015-2020)
Figure 43. GlaxoSmithKline Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. GlaxoSmithKline Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2015-2020)
Figure 45. UCB Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. UCB Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2015-2020)
Figure 47. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Amgen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2015-2020)
Figure 49. AbbVie Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. AbbVie Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2015-2020)
Figure 51. Takeda Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Takeda Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2015-2020)
Figure 53. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. AstraZeneca Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2015-2020)
Figure 55. Mylan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Mylan Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2015-2020)
Figure 57. LEO Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. LEO Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2015-2020)
Figure 59. Boehringer Ingelheim Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Boehringer Ingelheim Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2015-2020)
Figure 61. Alexion Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Alexion Pharmaceuticals Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2015-2020)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Similar Reports
This new 68-country report from LeadingMarketResearch.com is available by region, country, market segment, section, or individual test.
The report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global blood banking market during the next five years, and assist industry executives in developing effective business, new ...
- Publish Date: March 2, 2020
- $0
Hearing aids in the form of analog units have been traditionally present and used in India. Digital hearing units are finding increased growth in acceptability owing to the changing perceptions and growing base of the target consumer group. The Indian market is largely dependent on imports from foreign countries; domestic players in the country are ramping up their manufacturing facilities. The gr...
- Publish Date: March 10, 2011
- $950
The Indian medical devices market is largely dependent on imports from foreign countries. Although domestic players in the country are ramping up their manufacturing facilities, the foreign companies continue to enjoy a superior market share on account of their brand recognition, reliability, and technological superiority. The growing target base of consumers will boost sales and the market is exp...
- Publish Date: July 18, 2011
- $950
